Mirum Pharmaceuticals (MIRM) closed at $93.72 on November 6, 2026, up 0.2% from the previous close, on volume of 695,229 shares (30-day average 741,885).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
TipRanks (Fri, 6-Nov 2:15 AM ET)
Mirum Pharmaceuticals (MIRM) Receives a Rating Update from a Top Analyst
TipRanks (Thu, 5-Nov 9:32 AM ET)
TipRanks (Thu, 5-Nov 8:41 AM ET)
TipRanks (Thu, 5-Nov 1:00 AM ET)
Stifel Nicolaus Sticks to Their Buy Rating for Mirum Pharmaceuticals (MIRM)
TipRanks (Wed, 4-Nov 9:02 AM ET)
TipRanks (Wed, 4-Nov 9:00 AM ET)
Mirum Pharmaceuticals GAAP EPS of -$0.87 misses by $0.38, revenue of $185.7M beats by $7.66M
Seeking Alpha News (Tue, 3-Nov 4:03 PM ET)
Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
Business Wire (Tue, 3-Nov 4:01 PM ET)
Here are the major earnings after the close Tuesday
Seeking Alpha News (Tue, 3-Nov 10:00 AM ET)
Business Wire (Mon, 2-Nov 8:02 AM ET)
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
Mirum Pharmaceuticals trades on the NASDAQ stock market under the symbol MIRM.
As of November 6, 2026, MIRM stock price climbed to $93.72 with 695,229 million shares trading.
MIRM has a beta of 0.61, meaning it tends to be less sensitive to market movements. MIRM has a correlation of 0.03 to the broad based SPY ETF.
MIRM has a market cap of $5.71 billion. This is considered a Mid Cap stock.
Last quarter Mirum Pharmaceuticals reported $186 million in Revenue and -$.87 earnings per share. This beat revenue expectation by $8 million and missed earnings estimates by -$.43.
In the last 3 years, MIRM traded as high as $130.00 and as low as $23.14.
The top ETF exchange traded funds that MIRM belongs to (by Net Assets): VTI, XBI, IWM, VB, VBK.
MIRM has outperformed the market in the last year with a price return of +38.4% while the SPY ETF gained +10.8%. MIRM has also outperformed the stock market ETF in the last 3 month and 2 week periods returning -0.4% and +16.6%, respectively, while the SPY returned -4.1% and -3.2%, respectively.
MIRM support price is $90.25 and resistance is $96.83 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MIRM shares will trade within this expected range on the day.
